CSF1 and breast carcinoma: In both B16/F10 melanoma and 4T1 breast cancer models, the supramolecule demonstrated robust anti-tumor and anti-metastatic efficacy, suggesting that the simultaneous blockade of the CD47/SIRPα and CSF-1/CSF-1R signaling axes can be further explored as a potent immunotherapeutic strategy [46].